ESR1 and breast cancer: High levels of ctDNA were significantly correlated with decreased overall survival (OS) in breast cancer (BC) [2] and, more specifically, ESR1 cfDNA variants were associated with a shorter duration of endocrine treatment effectiveness in metastatic BC (MBC) [3].